DB
FULC icon

Dmitry Balyasny’s Fulcrum Therapeutics FULC Stock Holding History

Dmitry Balyasny’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-400,000
Closed -$3.07M – 3179
2026
Q1 		$3.07M Buy
+400,000
New +$3.71M ﹤0.01% 1586

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dmitry Balyasny's FULC Position: Q2 2026 in Review

Dmitry Balyasny reduced its Fulcrum Therapeutics (FULC) stake by 61% in Q2 2026, selling an estimated $6.62M and leaving 692,372 shares worth $2.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1699.

Dmitry Balyasny first reported a position in FULC in Q4 2021 and has held it in 12 quarters since. The position peaked at $13.7M in Q1 2026. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Dmitry Balyasny held 692,372 shares of Fulcrum Therapeutics worth $2.53M as of Q2 2026.
  • Dmitry Balyasny sold 1,087,574 Fulcrum Therapeutics shares in Q2 2026, an estimated $6.62M.
  • Fulcrum Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1699 holding.
  • Dmitry Balyasny first reported a position in Fulcrum Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Dmitry Balyasny's Fulcrum Therapeutics position peaked at $13.7M in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.